Milk Powder Synthetic Low Calcium
Recommended MetabolicRestrictedNot applicable line
Dietary management of hypercalcaemia in patients under the age of four years (inclusive).
1
Submissions
2020–20
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Jul 2020 Recommended Hypercalcaemia
Access path
- Jul 2020Recommended · restricted
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
6.1 The PBAC recommended continuing the Restricted Benefit listing of milk powder synthetic low calcium, Locasol, for the dietary management of hypercalcaemia of patients under the age of four years (inclusive), based on new European compositional standards.PSD · Jul 2020
6.2 The PBAC noted the NPWP had no concerns that the changes to the formulation would pose a risk to the health and safety of patients.PSD · Jul 2020
Cost-effectiveness
Not a clinical/economic submission; formulation change only. No ICER calculated.
Decision context
PopulationPatients under the age of four years (inclusive) requiring dietary management of hypercalcaemia.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2020 | Recommended · restricted | — | — | Other |
Similar precedents
Milk Powder Synthetic, Low Calcium Oral Powder98%High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein And Carbohydrate60%Amino Acid Synthetic Formula60%Amino Acid Synthetic Formula Supplemented With Long Chain Polyunsaturated Fatty Acids; Amino Acid Formula Supplemented With Prebiotics, Probiotics And Long Chain Polyunsaturated Fatty Acids61%Milk Powder - Lactose Intolerance Formula60%Triglycerides Medium Chain And Long Chain With Glucose Polymer60%Amino Acids – Synthetic, Formula59%Whey Protein Formula Supplemented With Amino Acids, Long Chain Polyunsaturated Fatty Acids, Vitamins And Minerals, Low In Protein, Phosphate, Potassium And Lactose58%